Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-09 4:05 pm Purchase | 2023-12-31 | 13G | Eton Pharmaceuticals, Inc. ETON | Opaleye Management Inc. | 2,524,887 9.840% | 354,887 (+16.35%) | Filing History |
| 2024-01-05 4:05 pm Purchase | 2023-12-27 | 13G | Context Therapeutics Inc. CNTX | Opaleye Management Inc. | 820,000 5.140% | 820,000 (New Position) | Filing History |
| 2023-04-12 4:15 pm Purchase | 2022-03-30 | 13G | Jounce Therapeutics, Inc. JNCE | Opaleye Management Inc. | 2,810,000 5.390% | 2,810,000 (New Position) | Filing History |
| 2023-02-13 4:05 pm Sale | 2022-12-30 | 13G | Chimerix, Inc. CMRX | Opaleye Management Inc. | 0 0.000% | -5,580,000 (Position Closed) | Filing History |
| 2023-02-13 4:05 pm Unchanged | 2022-12-30 | 13G | SANUWAVE Health, Inc. SNWV | Opaleye Management Inc. | 83,810 5.690% | 0 (Unchanged) | Filing History |
| 2023-02-13 06:11 am Purchase | 2022-12-30 | 13G | Ocular Therapeutix, Inc. OCUL | Opaleye Management Inc. | 6,075,000 7.890% | 100,200 (+1.68%) | Filing History |
| 2023-01-20 7:09 pm Purchase | 2022-12-31 | 13G | Larimar Therapeutics, Inc. LRMR | Opaleye Management Inc. | 1,560,000 3.610% | 616,298 (+65.31%) | Filing History |
| 2023-01-20 4:59 pm Purchase | 2022-12-31 | 13G | Harrow Health, Inc. HROW | Opaleye Management Inc. | 3,775,000 12.820% | 490,000 (+14.92%) | Filing History |
| 2023-01-20 4:53 pm Sale | 2022-12-31 | 13G | Eton Pharmaceuticals, Inc. ETON | Opaleye Management Inc. | 2,170,000 8.580% | -215,000 (-9.01%) | Filing History |
| 2022-06-10 4:05 pm Purchase | 2022-06-07 | 13D | TELA Bio, Inc. TELA | Opaleye Management Inc. | 1,557,500 10.690% | 806,332 (+107.34%) | Filing History |
| 2022-06-03 4:05 pm Purchase | 2022-06-01 | 13G | TELA Bio, Inc. TELA | Opaleye Management Inc. | 751,168 5.160% | 751,168 (New Position) | Filing History |
| 2022-02-18 4:32 pm Purchase | 2022-02-15 | 13G | Larimar Therapeutics, Inc. LRMR | Opaleye Management Inc. | 943,702 5.320% | 943,702 (New Position) | Filing History |
| 2022-01-31 9:02 pm Unchanged | 2021-12-31 | 13G | Chimerix, Inc. CMRX | Opaleye Management Inc. | 0 0.000% | 0 (Unchanged) | Filing History |
| 2022-01-31 8:41 pm Purchase | 2021-12-31 | 13G | Chimerix, Inc. CMRX | Opaleye Management Inc. | 5,580,000 6.400% | 1,623,500 (+41.03%) | Filing History |
| 2022-01-31 8:38 pm Sale | 2021-12-31 | 13G | Ocular Therapeutix, Inc. OCUL | Opaleye Management Inc. | 5,974,800 7.800% | -535,200 (-8.22%) | Filing History |
| 2022-01-26 11:06 am Unchanged | 2021-12-31 | 13G | SANUWAVE Health, Inc. SNWV | Opaleye Management Inc. | 83,810 6.500% | 0 (Unchanged) | Filing History |
| 2022-01-26 11:00 am Sale | 2021-12-31 | 13G | Adamas Pharmaceuticals, Inc. ADMS | Opaleye Management Inc. | 0 0.000% | -1,487,800 (Position Closed) | Filing History |
| 2022-01-25 9:43 pm Purchase | 2021-12-31 | 13G | Harrow Health, Inc. HROW | Opaleye Management Inc. | 3,285,000 12.200% | 219,584 (+7.16%) | Filing History |
| 2022-01-24 4:05 pm Sale | 2021-12-31 | 13G | Eton Pharmaceuticals, Inc. ETON | Opaleye Management Inc. | 2,385,000 9.690% | -1,307,700 (-35.41%) | Filing History |
| 2021-06-17 4:40 pm Purchase | 2020-12-31 | 13G | Eton Pharmaceuticals, Inc. ETON | Opaleye Management Inc. | 3,692,700 15.070% | 52,700 (+1.45%) | Filing History |